Cannabis Stocks Gain Following Rumors of Imminent Rescheduling
By Dean Seal
Cannabis stocks capped off a volatile week with gains after a prominent hedge fund manager suggested that regulators will soon reclassify marijuana as a less dangerous drug.
AdvisorShares Pure US Cannabis, a popular exchange-traded fund tracking marijuana stocks, was up 9% at $8.43 in late trading. After declines earlier this week, the ETF is now up from a week ago and has gained 20% year-to-date.
Shares of Curaleaf, the biggest U.S. cannabis company by revenue, were up more than 14% at $4.65. The stocks of Green Thumb Industries, Verano Holdings and Trulieve Cannabis, three major operators in the U.S., advanced around 6% to 9%.
Before the market opened, Dougie Kass of Seabreeze Capital Partners LP said on X, formerly known as Twitter, that his firm has learned the Drug Enforcement Administration will soon approve a rescheduling of cannabis down to a less restrictive category of drugs after overcoming an international legal hurdle.
The gains also come after Department of Health and Human Services Secretary Xavier Becerra testified before a U.S. Senate committee on Thursday and defended the Food and Drug Administration's review of cannabis' scheduling status.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 15, 2024 14:56 ET (18:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations